Elotuzumab: First Global Approval. - Wikidata - awgldk - TriplyDB

Elotuzumab: First Global Approval.

Elotuzumab: First Global Approval.

http://www.wikidata.org/entity/Q38711212

about

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma.

P2860

Q33574203-FF7AF44B-EB57-498C-B3F8-D6B8794393CF Q47100626-B56394EA-6D86-4B49-8E7A-E37D8E5E267F

P2860

Elotuzumab: First Global Approval.

http://www.wikidata.org/entity/Q38711212

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Elotuzumab: First Global Approval.

@en

type

label

Elotuzumab: First Global Approval.

@en

prefLabel

Elotuzumab: First Global Approval.

@en

P1433

Q38711212-AAD8AD20-70F6-47E5-8E8D-F39DC3084B11

P1476

Q38711212-4B254DE5-025E-449C-8CAB-E2970AE207F2

P2093

Q38711212-CBD65943-4826-4474-8120-5B59506DBAD8

P2860

Q38711212-7E9C0E1B-67E9-4EBA-B22E-F0AEBA25570D

Q38711212-8E3BFCD0-8B5F-439C-94F2-A50E659E7EBA

Q38711212-8E920E6B-8B24-4766-979E-2321A6C3CD6C

Q38711212-A3F67FFC-6421-4259-B078-1D12D7B4F33B

Q38711212-B722B869-62FB-456B-988E-5FC591C79A57

Q38711212-BADD1BD6-EDD5-4826-A737-968E38A3F57D

Q38711212-BC238C08-2ACA-484C-AB26-44F9721254DD

Q38711212-F2D69AB1-07C6-4117-A5B7-F3B011A857C4

P2888

Q38711212-4B3FE64F-CBF6-4805-8F57-01752BCAA339

P304

Q38711212-B0E22CF8-D212-4B02-A0EA-697D5E2E2F5F

P31

Q38711212-3AAEAE21-BAB9-4072-B42D-3F3AB978B838

P356

Q38711212-62360D0E-E6E8-4991-9365-157C417C5CEA

P433

Q38711212-90F51CAC-0259-4DED-8B79-DC19A7067F51

P478

Q38711212-740AC347-151B-4423-94CD-5E357B377D99

P577

Q38711212-329432EA-A368-401C-8087-5966ED8F340A

P6179

Q38711212-D60A892C-DA3B-4022-A36E-C4134C3B4CC9

P698

Q38711212-2FF9F249-B7C9-4E6B-A06F-24036581687A

P356

S40265-016-0540-0

P1433

P1476

Elotuzumab: First Global Approval.

@en

P2093

Anthony Markham

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.

P2888

s40265-016-0540-0

P304

397-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0540-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1004568872

http://www.w3.org/2001/XMLSchema#string

P698

26809244

http://www.w3.org/2001/XMLSchema#string